Anbio Biotechnology Class A Ordinary Shares
NNNN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $11,761 | $9,688 | $7,102 | $4,181 |
| Short-Term Investments | $0 | $0 | $1,567 | $0 |
| Receivables | $1,065 | $1,885 | $4 | $718 |
| Inventory | $0 | $0 | $354 | $0 |
| Other Curr. Assets | $5,709 | $4,177 | $4,917 | $17 |
| Total Curr. Assets | $18,534 | $15,750 | $13,943 | $4,916 |
| Property Plant & Equip (Net) | $0 | $0 | $12 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $387 | $62 | $3 | $0 |
| Total NC Assets | $387 | $62 | $15 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $18,922 | $15,812 | $13,958 | $4,916 |
| Liabilities | – | – | – | – |
| Payables | $1,625 | $827 | $1,408 | $1,890 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $490 |
| Other Curr. Liab. | $105 | $166 | $3 | $0 |
| Total Curr. Liab. | $1,730 | $993 | $1,411 | $2,380 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,730 | $993 | $1,411 | $2,380 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $14 | $14 | $0 | $0 |
| Retained Earnings | $17,174 | $14,801 | $12,547 | $2,536 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $4 | $4 | $0 | $0 |
| Total Equity | $17,192 | $14,819 | $12,547 | $2,536 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $18,922 | $15,812 | $13,958 | $4,916 |
| Net Debt | -$11,761 | -$9,688 | -$7,102 | -$4,181 |